GlassScriptPhysician profile
Irene Gomez
NPI 1861751026
$1,162.27
in general payments reported to CMS, 2019-2025
14 companies · $728 in 2025
The $728 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $435 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $213.57 | 2024-2025 | Repatha, Repatha |
| Stryker Corporation | $169.85 | 2025 | Limflow System |
| Cvrx, INC. | $159.13 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $116.22 | 2025 | Lokelma |
| Novartis Pharmaceuticals Corporation | $106.79 | 2024-2025 | |
| Edwards Lifesciences Corporation | $105.48 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $78.23 | 2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $61.63 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $38.12 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.98 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $27.03 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.17 | 2025 | Jardiance |
| Coloplast Corp | $20.62 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.